



SynVision Chem

INNOVATION EXCELLENCE

YOUR PARTNER FOR

Custom
Synthesis

Process
Development

Medicinal
Chemistry

CRAM

 19/A, Punit Industries, D-1 Block MIDC Chinchwad, Pune: 411019

 +91 8530390457 / +91 9765800457

 info@synvisionchem.com

 <http://www.synvisionchem.com>



SynVision Chem


INNOVATION EXCELLENCE

Custom
Synthesis

- Tailor-made molecules from mg to multi-kg
- Design and synthesis of novel APIs and intermediates.
- Impurities and reference standards for regulatory submissions.
- Multi-step organic synthesis of challenging structures.

**Delivered over 100 projects in last three years
with 85% Success Rate**

Reference Compound




Feruloyl putrescine


Agro-Chemicals




Difenthruron




API




Acoramidis



Mesdopetam



Obefazimod



Mesdopetam



SynVision Chem


INNOVATION EXCELLENCE

Process Development


From lab route to robust, plant-ready process

- Route scouting and selection for a sustainable and economic process.
- Process optimization for yield, purity and cycle time
- Identification and control of critical process parameters.
- Development of robust, reproducible procedures


API KSM and Intermediates developed on an exclusive basis




Suvorexant KSM



Chlorphthalidone KSM




Apixaban KSM



Ziprasidone KSM



Boc-Lys(Boc)-OH and DCHA Salt



Semaglutide KSM




SynVision Chem

INNOVATION EXCELLENCE

Our
Products

Tapinarof




Status: API / Intermediates / Impurities Available

Novel (patented) process available for licensing

Tapinarof is a first-in-class aryl hydrocarbon receptor (AhR) agonist, approved by the U.S. FDA in 2022 for the treatment of psoriasis and atopic dermatitis.

Acoltremon




Novel Process

Status: API/Intermediates Available

Acoltremon is a TRPM8 agonist, approved by the U.S. FDA in 2025 for the treatment of Dry Eye Disease.

Acoramidis



Status: API/Intermediates/Impurities Available

Acoramidis is an approved drug used for the treatment of transthyretin (TTR) amyloidosis.



SynVision Chem
INNOVATION EXCELLENCE

Capabilities

R&D LAB DESIGNED FOR CHALLENGING CHEMISTRY

- Fully equipped synthetic R&D lab dedicated to custom synthesis and process development.
- Set up to handle a wide range of organic reactions and multi-step syntheses.
- Infrastructure to support Inert atmosphere, temperature-controlled reactions and scalable process development.

Analytical Support:

- HPLC-UV/PDA/CAD Systems
- GC, GC-HS, GC-Mass Spectrometry
- LC-MS & LC-MS/MS
- Preparative LC Systems
- Karl Fischer (KF) Titration

Pilot and Manufacturing:

- Pilot-scale reactors up to 200 L for scale-up and process verification.
- Capability to handle custom synthesis from mg to multi-kg quantities.




SynVision Chem
INNOVATION EXCELLENCE

Value
Addition

From the first milligram to the final batch
data-backed decisions at every step.

- End-to-end solution



Value Creation for Your Business

- Enrich your product portfolio.
- Minimize R&D cost.
- Maximise the Success-to-Risk ratio for new product development.
- Use your facility at maximum capacity.
- Accelerate time-to-market.
- Reduce technical & supply risk with robust, documented routes.
- Improve sustainability with greener processes.

SHARE YOUR REQUIREMENT [CLICK HERE](#)

 19/A, Punit Industries, D-1 Block MIDC Chinchwad, Pune: 411019

 +91 8530390457 / +91 9765800457

 info@synvisionchem.com

 <http://www.synvisionchem.com>